<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254746</url>
  </required_header>
  <id_info>
    <org_study_id>CHUV-DO-HYPORT-2013</org_study_id>
    <nct_id>NCT02254746</nct_id>
  </id_info>
  <brief_title>A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer</brief_title>
  <official_title>A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the safety and efficacy of Stereotactic Body Radiation&#xD;
      Therapy (SBRT) in localized prostate carcinoma in patients for whom the standard treatment is&#xD;
      the irradiation of the entire prostate gland with or without seminal vesicles accompanied or&#xD;
      not by hormonal therapy. In light of the accumulating clinical evidence favoring the use of&#xD;
      hypo fractionation, SBRT regimen might constitute a much more convenient non-invasive and&#xD;
      highly efficient outpatient therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective phase I:&#xD;
&#xD;
      To irradiate the prostate gland which might albeit contain microscopic disease with&#xD;
      tumoricidal doses of SBRT, and to escalate the dose of SBRT in the visible prostatic tumor&#xD;
      towards the best tumoricidal dose without exceeding the normal tissue tolerance and toxicity&#xD;
      in patients with organ confined T2-T3 N0 prostate carcinoma.&#xD;
&#xD;
      Primary objective phase II:&#xD;
&#xD;
      To determine the rate of acute toxicity grade 2 or more defined as toxicity occurring&#xD;
      immediately after the first fraction of radiotherapy and up to 90 days after the start of&#xD;
      radiotherapy treatment.&#xD;
&#xD;
      Secondary objectives phase II:&#xD;
&#xD;
        -  To determine efficacy measured by PSA failure using Phoenix definition.&#xD;
&#xD;
        -  To determine long-term late toxicity (&gt;90 days after treatment start).&#xD;
&#xD;
      Exploratory endpoint phase II:&#xD;
&#xD;
      • To determine the feasibility of achieving dose constraints in the organs at risk using high&#xD;
      technology radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (phase I)</measure>
    <time_frame>During the first 30 days from the start of treatment</time_frame>
    <description>Observation of dose-limiting toxicities (DLT) defined as any treatment-related grade ≥ 3 acute toxicity occurring in the radiation field or irradiated volumes in the following categories GI or GU. In addition, any other grade 4 or 5 toxicity attributed to the therapy constitutes a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity (phase II)</measure>
    <time_frame>90 days after the first fraction of radiotherapy treatment</time_frame>
    <description>Acute GU and GI toxicity (grade 2 or more) according to the NCI CTCAE v4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (phase II)</measure>
    <time_frame>3 monthly assessments during the first 2 years and 6 monthly assessments until end of study (5 years)</time_frame>
    <description>PSA failure using Phoenix definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (phase II)</measure>
    <time_frame>&gt; 90 days and up to 5 years from the start of protocol treatment</time_frame>
    <description>Long term GU and GI toxicity (grade 2 or more) according to the NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Phase I (dose escalation)/ Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I&#xD;
Prostate tumor: starting dose 9 Gy per fraction in 5 fractions (total 45 Gy) and subsequent dose escalation up to 10 Gy.&#xD;
Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions (no dose escalation). Total 36.25 Gy.&#xD;
Phase II&#xD;
Additional patients will be treated at either the maximum tolerated dose (MTD) or at the highest dose level as determined by the investigators from the Phase I portion of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy (SBRT)</intervention_name>
    <arm_group_label>Phase I (dose escalation)/ Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients must be willing and capable to provide informed consent&#xD;
&#xD;
          -  Histologic confirmation of prostate adenocarcinoma&#xD;
&#xD;
          -  T2-T3 tumors, N0 (clinically by no evidence of metastatic lymph nodes on CT or MRI)&#xD;
&#xD;
          -  No direct evidence of regional or distant metastases&#xD;
&#xD;
          -  PSA less than or equal to 50 μg/ml&#xD;
&#xD;
          -  Visible gross tumor at the prostate endorectal coil MRI.&#xD;
&#xD;
          -  The ultrasound or MRI based volume estimation of the patient's prostate gland no&#xD;
             greater than 70g or 70cc&#xD;
&#xD;
          -  No significant urinary obstructive symptoms; IPSS score must be ≤ 15 (alpha blockers&#xD;
             allowed)&#xD;
&#xD;
          -  Patient must have undergone an endorectal coil magnetic resonance image (MRI) of the&#xD;
             prostatic gland (before rectal spacer if any),&#xD;
&#xD;
          -  Patient must have undergone the following assessments in case of PSA ≥ 20μg/L, and/or&#xD;
             T3 tumor and/or Gleason Score ≥ 8:&#xD;
&#xD;
               -  bone scan&#xD;
&#xD;
               -  Chest abdominal and pelvis computed tomography (CT) scan&#xD;
&#xD;
          -  If tumor is localized at less than 3 mm from the rectum a rectal spacer is mandatory.&#xD;
             Patient accepts the rectal spacer to be injected before treatment starts&#xD;
&#xD;
          -  Patient accepts to have one planning MRI after the injection of rectal spacer (without&#xD;
             endorectal coil)&#xD;
&#xD;
          -  Patient accepts the preparation of the bladder (bladder full), before the planning&#xD;
             MRI, planning CT and then before each treatment fraction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiotherapy in the pelvis&#xD;
&#xD;
          -  Tumor localized at less than 3 mm from the urethra&#xD;
&#xD;
          -  History of inflammatory colitis (including Crohn's disease and ulcerative colitis)&#xD;
&#xD;
          -  Prior cancer in the pelvis&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the patient before inclusion in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernanda Herrera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Dr Fernanda Herrera</investigator_full_name>
    <investigator_title>Cheffe de clinique</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

